Home » Stocks » NXTC

NextCure, Inc. (NXTC)

Stock Price: $7.86 USD 0.17 (2.21%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 212.32M
Revenue (ttm) 22.38M
Net Income (ttm) -36.60M
Shares Out 27.53M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $7.86
Previous Close $7.69
Change ($) 0.17
Change (%) 2.21%
Day's Open 7.83
Day's Range 7.63 - 7.99
Day's Volume 480,483
52-Week Range 7.63 - 39.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

1 week ago - GlobeNewsWire

Other stocks mentioned: CHFS, HAPP
3 weeks ago - GuruFocus

BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

3 weeks ago - GlobeNewsWire

BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

4 weeks ago - GlobeNewsWire

BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

2 months ago - GlobeNewsWire

BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

2 months ago - GlobeNewsWire

BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

2 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - February 11, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....

2 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

3 months ago - Business Wire

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

3 months ago - GlobeNewsWire

These companies are eager to say good riddance to the year that was.

Other stocks mentioned: AMRN, ICPT, IVR, NGL, PBF, SNDL, TCDA ...
4 months ago - The Motley Fool

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “th...

4 months ago - Business Wire

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

4 months ago - GlobeNewsWire

NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact...

5 months ago - GlobeNewsWire

BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...

5 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - November 19, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ...

5 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action fil...

5 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - November 17, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 16, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....

5 months ago - Newsfile Corp

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14...

5 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - November 13, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc....

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November ...

5 months ago - Newsfile Corp

BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...

6 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclu...

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 31, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...

6 months ago - Newsfile Corp

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 23, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November ...

6 months ago - Newsfile Corp

LOS ANGELES, Oct. 22, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on b...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 17, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5...

6 months ago - Newsfile Corp

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14,...

6 months ago - PRNewsWire

BENSALEM, Pa., Oct. 8, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behal...

6 months ago - PRNewsWire

LOS ANGELES, Oct. 6, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Nex...

7 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclu...

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 2, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of N...

7 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure” or "the Company") (NASDAQ:NXTC) and certain...

7 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Deadline in the Class Action Against NextCure,Inc.(NXTC)on Behalf of Investors

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) of...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure" or "the Co...

7 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action of a Securities Class Action Lawsuit Against NextCure, Inc. (NXTC)

7 months ago - Business Wire

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NA...

7 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has be...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

7 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that: (i) purchased or acqu...

7 months ago - Business Wire

SAN DIEGO & BELTSVILLE, Mass.--(BUSINESS WIRE)---- $NXTC #ClassAction--Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action against th...

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

7 months ago - Business Wire

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1;... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2019
Stock Exchange
NASDAQ
Ticker Symbol
NXTC
Full Company Profile

Financial Performance

In 2020, NextCure's revenue was $22.38 million, an increase of 252.58% compared to the previous year's $6.35 million. Losses were -$36.60 million, 8.50% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for NextCure stock is "Buy." The 12-month stock price forecast is 19.38, which is an increase of 146.56% from the latest price.

Price Target
$19.38
(146.56% upside)
Analyst Consensus: Buy